News

First-in-human trial of NILK-2401, a CEACAM5xCD47 bispecific κλ body

Structural analysis of light chain-driven bispecific antibodies targeting CD47 andPD-L1

First-in-human trial of a CEACAM5xCD3 bispecific κλ body for solid cancer

Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody

AACR Annual Meeting 2024 - Sara Majocchi -

Antibody Engineering & Therapeutics Europe- Sara Majocchi -

Antibody Engineering & Therapeutics Europe - Nicolas Fischer & Sara Majocchi -

19th annual PEGS Boston - Nicolas Fischer -

AACR Annual Meeting 2023 - Walter Ferlin & Xavier Chauchet -

Sara Majocchi

14th annual PEGS Europe - Sara Majocchi -

37th Annual Meeting & Pre-Conference Programs (SITC)

Xavier Chauchet, Laura Cons, et al.

AACR Annual Meeting 2022 - Xavier Chauchet -

AACR Annual Meeting 2022 - Sara Majocchi -

We are looking forward to meeting you in person at the follwing events.

36th Annual Meeting & Pre-Conference Programs (SITC)

Our partner Edesa Biotech announced positive Phase 2 Data for the licensed anti-TLR4 monoclonal antibody in hospitalized COVID-19 patients

A Swiss biotech success story award has been attributed to Novimmune at the recent Swiss Biotech days held in Basel.

"PARLONS ECONOMIE" - Is the future of medicine taking shape in Geneva?

Global collaboration with TG Therapeutic (NSDAQ: TGTX).

22nd program of "Le Monde de Demain" dedicated to biotechnologies.

Nicolas Fischer, CEO introduces Light Chain Bioscience | Novimmune SA.

Light Chain Bioscience has entered into two research collaborations and worldwide licensing agreements with Discoveric bio group.

Milestones achieved under research collaboration with LamKap Bio.

Antibodies being used as a T-cell targeting system to wipe out cancer cells.

CD47 is a potent “don’t eat me” signal that enables cancer cells to evade immune surveillance and killing by innate immune cells, such as macrophages.

The 3 companies enter Licensing Agreement for Antibody Drug Conjugate program.

Both companies joined their forces to develop Treatments for COVID- 19 Pneumonia and Other Disorders.

Bispecific κλ bodies targeting CD47 and membrane proximal epitopes on MSLN afford enhanced efficacy in vitro and in vivo.

Light Chain Bioscience is leveraging its proprietary bispecific antibody format to advance immune therapies in oncology and beyond.

Light Chain Bioscience successfully completes Factor VIII mimetic bispecific antibody discovery for Takeda.

NovImmune SA is excited to be launching today the all new company website and branding.